General
Preferred name
solifenacin
Synonyms
SOLIFENACIN SUCCINATE ()
YM905 free base ()
YM905 ()
solifenacin succinate, ODT ()
Solifenacin (Succinate) ()
Solifenacin (hydrochloride) ()
YM905 (free base) ()
YM905 hydrochloride ()
Solifenacin hydrochloride ()
Solifenacin (YM905) ()
YM-905 ()
Vesicare ls ()
YM-67905 ()
Vesicare ()
YM67905 ()
Solifenacina ()
NSC-759144 ()
Solifenacine ()
Solifenacin-d5 (succinate) ()
P&D ID
PD014451
CAS
180468-39-7
242478-38-2
1172613-99-8
242478-37-1
Tags
available
drug
Approved by
FDA
First approval
2004
Drug indication
Overactive bladder
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
PRICE
29
DESCRIPTION
Solifenacin hydrochloride (YM905 hydrochloride) is a muscarinic receptor antagonist, with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
MOA
Solifenacin is a competitive muscarinic acetylcholine receptor antagonist with greatest activity at the M3 receptor. Inhibition of these receptors lowers smooth muscle tone in the bladder, preventing contractions and reducing incontinence.
PRICE
29
DESCRIPTION
Solifenacin (YM905 free base) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
DESCRIPTION
Solifenacin succinate (YM905) is a quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Muscarinic M3 receptor antagoinst. Used in treatment of urinary incontinence.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Solifenacin (YM905 free base) (YM905 free base) is a novel muscarinic receptor antagonist, its pKis for M1, M2 and M3 receptors is of 7.6, 6.9 and 8.0, respectively.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
24
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
VGSC-DB
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
78
Molecular Weight
362.2
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
6
Aromatic Ring Count
2
cLogP
3.86
TPSA
32.78
Fraction CSP3
0.43
Chiral centers
2.0
Largest ring
6.0
QED
0.81
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
mAChR
muscarinic receptor
CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AChR
Member status
member
MOA
NVP-CEH592 is a competitive cholinergic receptor antagonist
acetylcholine receptor antagonist
Indication
urinary incontinence, urinary frequency
Pathway
Neuroscience
GPCR/G protein
Neuronal Signaling
Therapeutic Class
Antispasmodics
VGSC Target
Nav1.5
Source data
